Alzheimer’s player Anavex reveals SEC probe; shares dive

John Carroll Shares of Anavex took a nasty hit after the New York-based biotech issued a 10-K this morning that included news of an SEC probe, evidently focused on "unusual" ...

Grifols bags €100M for Alzheimer’s R&D; Ipsen inks $137M cancer deal; Oryzon raises €17M

Nick Paul Taylor In this week's EuroBiotech Report, Catalan biotech Grifols secured a €100 million ($ 110 million) loan from the European Investment Bank's €315 billion ...

Feds clamp a hold on Forum’s PhIII Alzheimer’s study following GI events

John Carroll The FDA has slammed the brakes on the late-stage Alzheimer's development program for encenicline after investigators reported a "small" number of serious ...

Roche’s $100M Alzheimer’s study could shift the balance in R&D

Damian Garde Despite all the excitement over Biogen's recent Phase I success in Alzheimer's, the question of whether attacking protein buildups in the brain can in fact treat ...

Novartis makes Israel a priority, U.K. dreams up Alzheimer’s R&D hub, Shire defends tax model

Nick Paul Taylor In this week's EuroBiotech Report, Novartis is getting deeper into the Israeli biotech scene, tasking BioLineRx with keeping tabs on local startups after realizing ...

Investigators link Novartis’ would-be cardio blockbuster to Alzheimer’s risk

John Carroll Novartis' heart failure med LCZ696 has singlehandedly saved the pharma giant's cardio drug development strategy from the embarrassing setback triggered by serelaxin's ...

Astellas backs out of a $760M Alzheimer’s deal with CoMentis

Damian Garde Astellas and CoMentis are calling it quits on their partnership in Alzheimer's disease, as the Japanese drugmaker walks away from a deal valued at up to $ 760 million. FierceBiotech ...

Alzheimer’s R&D suffers as trial failure rate hits an ‘astounding’ 99.6%

John Carroll Jeffrey Cummings is directing one of the few early-stage studies underway on an Alzheimer's therapy. And now that he's scanned the records of clinicaltrials.gov, ...

Chase banks $21M round for Alzheimer’s drug research

John Carroll Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $ 21 million ...

Billionaire backs new program for a pioneering Alzheimer’s vaccine from AC Immune

John Carroll German billionaire Dietmar Hopp is adding to his multimillion-dollar wager on AC Immune, the Swiss biotech that is playing a key role in some high-profile Alzheimer's ...

Lundbeck stakes out a leading role for itself in late-stage Alzheimer’s R&D

John Carroll While Alzheimer's has long reigned as one of the most challenging fields in R&D, it has also provided some of the most confident projections in the industry. And ...

J&J innovation team sets up international collaboration to discover Alzheimer’s drugs

John Carroll J&J has spent hundreds of millions of dollars in a so-far failed effort to develop a late-stage biologic that could be used to treat Alzheimer's. And it's now ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS